Cabergoline

Cabergoline
Clinical data
Trade names	Dostinex, others
AHFS/Drugs.com	Monograph
License data	US DailyMed: Cabergoline;
Routes of; administration	By mouth
ATC code	G02CB03 (WHO) N04BC06 (WHO);
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	First-pass effect seen; absolute bioavailability unknown
Protein binding	Moderately bound (40–42%); concentration-independent
Metabolism	Liver, predominately via hydrolysis of the acylurea bond or the urea moiety
Elimination half-life	63–69 hours (estimated)
Excretion	Urine (22%), feces (60%)
Identifiers
	IUPAC name (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	81409-90-7 ;
PubChem CID	54746;
IUPHAR/BPS	37;
DrugBank	DB00248 ;
ChemSpider	49452 ;
UNII	LL60K9J05T;
KEGG	D00987 ;
ChEBI	CHEBI:3286 ;
ChEMBL	ChEMBL1201087 ;
CompTox Dashboard (EPA)	DTXSID6022719 ;
ECHA InfoCard	100.155.380
Chemical and physical data
Formula	C26H37N5O2
Molar mass	451.615 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [H][C@]12C[C@@H](C(=O)N(CCCN(C)C)C(=O)NCC)CN(CC=C)[C@]1([H])Cc3c[nH]c4cccc2c34;
	InChI InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1 ; Key:KORNTPPJEAJQIU-KJXAQDMKSA-N ;
	(what is this?) (verify)

Cabergoline, sold under the brand name Dostinex among others, is a dopaminergic medication used in the treatment of high prolactin levels, prolactinomas, Parkinson's disease, and for other indications.^[1] It is taken by mouth.

Cabergoline is an ergot derivative and a potent dopamine D₂ receptor agonist.^[2]

Cabergoline was patented in 1980 and approved for medical use in 1993.^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

^ "Cabergoline: MedlinePlus Drug Information". medlineplus.gov. Retrieved 2023-10-22.
^ Elks J, Ganellin CR (1990). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 204–.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 533. ISBN 9783527607495.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.